Bayer
Belief BioMed, Bayer's AskBio to Collaborate on Liver-Targeted Gene Therapies
As part of the deal, the companies said they will work together to advance gene therapies for diseases with high unmet medical need.
Bayer Begins Phase III Trial of EGFR, HER2 Inhibitor in First-Line HER2-Mutant NSCLC
The firm will compare how BAY 2927088 impacts progression-free survival compared to Keytruda plus chemo in around 280 patients.
FDA Approves Illumina Cancer Genomic Profiling Assay as CDx for Kinase Inhibitors From Bayer, Lilly
The test's first CDx approvals are for Bayer's Vitrakvi in solid tumors and for Lilly's Retevmo in non-small cell lung cancer.
In Brief This Week: Helio Genomics, VolitionRx, Mainz Biomed, Abeona, Obsidian, Eisai, Biogen
News items for the weeks of July 1 and July 8, 2024.
Bayer's AskBio Starts Enrolling Parkinson's Patients in Phase II Gene Therapy Trial
In the clinical trial, the company will assess the safety and efficacy of AB-1005, a gene therapy designed to deliver a functional copy of GDNF.